Improving survival and quality of life
Our vision
PREMIO COLLAB is dedicated to improving survival and quality of life for patients living with metastatic breast cancer.
Our mission is to modernize the way treatment response is monitored, ensuring that diagnostic care becomes more precise, patient-focused, and efficient.
By combining scientific innovation with patient perspectives, we aim to create a new standard for monitoring and managing metastatic breast cancer and supporting those living with it and their carers.
Why change is needed
For decades, doctors have used the same diagnostic methods to check how well modern treatments are working for patients with metastatic breast cancer. But medical technology has come a long way.
One major advancement is FDG-PET/CT, a type of scan that combines two powerful imaging techniques:
FDG-PET
(Flouro-deoxy-glucose Positron Emission Tomography)
CT
(Computed Tomography)
Together, FDG-PET/CT gives doctors a clearer and more accurate image of where cancer is and over time how it is responding to treatment. This can help guide better treatments decisions and thereby expectedly improve survival.
Closing the evidence gap in metastatic breast cancer care
Despite these benefits, we lack evidence to inform international guidelines and therefore, they still have no clear recommendations on how to use scans for ongoing treatment monitoring in patients with metastatic breast cancer.
Moreover, the patient perspective in living with metastatic breast cancer is often overlooked, even though frequent monitoring scans can affect their daily life for years.
PREMIO COLLAB aims to close these gaps by combining the latest science with a focus on what matters most to the patients.
Our approach
PREMIO COLLAB brings together leading cancer centres, clinicians, researchers, patient representatives, and technology innovators across Europe in a unique collaborative effort.
In a large study involving 11 hospitals across 3 countries, and involving 7 countries, this project will compare different types of scans to see whether one helps people with metastatic breast cancer live longer and feel better during treatment.
What we learn from this project will help us create better care pathways and smarter digital tools—designed with patients, not just for them. By involving patients in every step, we make sure their voices shape the future of cancer care.
Looking ahead, we will explore exciting innovations like AI-powered imaging and liquid biopsies (simple blood tests that can detect cancer changes) to develop even more advanced ways to monitor and guide treatment decisions.
Our goal
The goal of PREMIO COLLAB is to generate robust evidence that informs future international recommendations on choice of methods for monitoring metastatic breast cancer and supports real-world implementation.
By combining technological innovation with patient voices, we aim to create a smarter, more humane approach to cancer care, benefiting patients, healthcare professionals, and society as a whole.
Collaboration across the globe
This initiative is part of the EU Cancer Mission’s “Diagnostics and Treatment” cluster and involves multiple European centres and living labs. Our work is grounded in collaboration, bringing together diverse expertise to tackle one of the most complex challenges in oncology.
Follow us
Learn more about our mission, explore our research, and join us in creating better outcomes for patients everywhere.